Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $11.8500 (-6.25%) ($11.6300 - $12.7300) on Mon. Apr. 8, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.31% (three month average) | RSI | 64 | Latest Price | $11.8500(-6.25%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA advances 3.6% a day on average for past five trading days. | Weekly Trend | IOVA advances 10% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(48%) XBI(48%) ARKG(47%) IWO(43%) ARKK(41%) | Factors Impacting IOVA price | IOVA will decline at least -2.155% in a week (0% probabilities). VXX(-13%) VIXM(-8%) UUP(-7%) IFRA(-5%) TLT(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.155% (StdDev 4.31%) | Hourly BBV | 0 () | Intraday Trend | -6.3% | | | |
|
5 Day Moving Average | $11.67(1.54%) | 10 Day Moving Average | $10.68(10.96%) | 20 Day Moving Average | $10.37(14.27%) | To recent high | -6.3% | To recent low | 40.9% | Market Cap | $1.735b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |